Pricing Log in Create free account
Friday 6 November 2026 Export CGON’s income statement to Excel — free account

CG Oncology, Inc.

CGON Healthcare Biotechnology

CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.

Revenue
−3.72%
EPS
−12.3%
Free cash flow
−25.2%
Total debt
0.00%

Quarter to September 2026, against a year earlier

76.08 11.28 +17.41%
Market cap
$5.7B
P/E
0.0×
Fwd P/E
−19.5×
Dividend yield
—
F-score
2/9
Altman Z
49.04
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

CG Oncology, Inc. (CGON) Book value per share

Alert me on Book value per share

CG Oncology, Inc.'s book value per share at the end of fiscal 2025 was 9.7×, down 17.0% from 11.7× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 11.2×. CG Oncology, Inc. ranks 70th of 611 Biotechnology companies by book value per share.

Book value per share, annual

Embed this chart

Annual newest first

Period Book value per share Change
FY2025 9.7× (17.03%)
FY2024 11.7× —
FY2023 −28.4× —
FY2022 −20.8× —

Quarterly newest first

Period Book value per share Change
Sep 2026 11.2× (4.43%)
Jun 2026 11.7× (9.67%)
Mar 2026 12.9× 32.68%
Dec 2025 9.7× 8.63%
12 more quarters

Book value per share against peers

Company Book value per share
LGND Ligand Pharmaceuticals Incorporated compare 48.2×
MANE Veradermics Incorporated compare 20.1×
BLTE Belite Bio, Inc. Sponsored ADR compare 19.3×
CGON CG Oncology, Inc. 11.7×
IMVT Immunovant, Inc. compare 3.6×
SRRK Scholar Rock Holding Corporation compare 1.9×
KOD Kodiak Sciences Inc. compare 1.0×
MIRM Mirum Pharmaceuticals, Inc. compare −0.8×
PTCT PTC Therapeutics, Inc. compare −2.3×

What Book value per share is

BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.

(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))

The full definition of Book value per share →

More on CGON